Top 10 Oncology Capital Raises and Investors in the U.S. – November 16th – December 31st, 2025
Several interesting transactions closed in the Oncology sector over the past two weeks. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.
PIPE
-
- Citius Oncology, biopharmaceutical company that develops and commercializes targeted oncology therapies, received $18 million of development capital through a private placement.
- Tempest Therapeutics, late-stage development biotechnology company that develops small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity, received approximately $4.25 million of development capital through a private placement.
Merger/Acquisition
-
- Mural Oncology, clinical-stage oncology company that discovers and develops immunotherapies that may meaningfully improve the lives of patients with cancer, was acquired by Xoma for $36.2 million.
- OneOncology, hospital and clinical network that manages independent oncology practices, was acquired by Cencora for $7.4 billion.
Later Stage VC
-
- Mel-Mont Medical, advanced molecular diagnostics for the early detection and prevention of RNA-virus-related pathologies, raised $6.90 million of venture funding.
- TRIANA Biomedicines, pharmaceutical company that discovers and develops molecular glues, raised $120.06 million of Series B venture funding in a deal led by Bessemer Venture Partners and Ascenta Capital.
Early Stage VC
-
- Bio Usawa, biotechnology firm that produces lifesaving and affordable monoclonal antibodies, raised $1.71 million of venture funding.
- Link Cell Therapies, cell therapies that helps doctors detect solid cancer tumors, raised $60 million through a combination of Series A-1 and Series A-2 venture funding in a deal led by Johnson & Johnson JJDC and Samsara BioCapital.
Seed
-
- RadioClash, interventional oncology device that enhances electroporation therapy for advanced cancer therapeutics, raised $1.38 million of seed funding from Symbiotic Ventures and other investors.
- SLAM BioTherapeutics, oncology and autoimmune therapies that provides monoclonal antibodies for cancer and autoimmune diseases, raised $1 million of seed funding in the form of convertible debt.
#castleplacement #capitalraising #privateequity #venturecapital #investment #Oncology
Gary Levy
Managing Director
Over 30 years in financial services, including senior roles at Citi, Ivy Asset Management (an Affiliate of BNY) and TIAA. Founder and President of Biltmore Savings Consultants, a provider of B2B technology solutions to improve operations. Author of published book "21 Ways to Improve Your Business Operations." MBA - Strategic Business Management from Hofstra University’s Frank G. Zarb School of Business. BS (with a concentration in Business, Management and Economics) from SUNY Empire State College. Series 7, 63 and 79 licenses.
- Email: glevy@castleplacement.com
- (C) (516) 457-0104
 Gary LevyManaging Director |
Please contact me if you have any questions or would like to discuss your capital raise:
Email: glevy@castleplacement.com
(C) (516) 457-0104
Send us a message:
Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement® does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.
